{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T18:55:04Z","timestamp":1740164104061,"version":"3.37.3"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,10]],"date-time":"2024-11-10T00:00:00Z","timestamp":1731196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,10]],"date-time":"2024-11-10T00:00:00Z","timestamp":1731196800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Sejer Persson og Lis Kl\u00fcwer Perssons Legat","award":["160322"],"award-info":[{"award-number":["160322"]}]},{"DOI":"10.13039\/501100008241","name":"Desir\u00e9e og Niels Ydes Fond","doi-asserted-by":"publisher","award":["534-22"],"award-info":[{"award-number":["534-22"]}],"id":[{"id":"10.13039\/501100008241","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-79334-x","type":"journal-article","created":{"date-parts":[[2024,11,10]],"date-time":"2024-11-10T09:10:16Z","timestamp":1731229816000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Assessing expression patterns of PTGR1, a potential biomarker for acylfulven sensitivity in urothelial carcinoma"],"prefix":"10.1038","volume":"14","author":[{"given":"Dag Rune","family":"Stormoen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Signe","family":"Lehn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kent W.","family":"Mouw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zoltan","family":"Szallasi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linea Cecilie","family":"Melchior","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Line Hammer","family":"Dohn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judit","family":"B\u00f6rcsok","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Rossing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Birgitte Gr\u00f8nkaer","family":"Toft","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helle","family":"Pappot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,11,10]]},"reference":[{"key":"79334_CR1","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1007\/s00345-023-04408-w","volume":"41","author":"DJ Reesink","year":"2023","unstructured":"Reesink, D. J. et al. Real-world outcomes of first-line chemotherapy for unresectable stage III and IV bladder cancer. World J. Urol. 41, 1551\u20131562 (2023).","journal-title":"World J. Urol."},{"key":"79334_CR2","doi-asserted-by":"publisher","first-page":"227","DOI":"10.3233\/BLC-170149","volume":"4","author":"MD Galsky","year":"2018","unstructured":"Galsky, M. D. et al. Real-world effectiveness of Chemotherapy in Elderly patients with metastatic bladder Cancer in the United States. Bladder Cancer. 4, 227\u2013238 (2018).","journal-title":"Bladder Cancer"},{"key":"79334_CR3","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.7150\/jca.23162","volume":"9","author":"G Niegisch","year":"2018","unstructured":"Niegisch, G. et al. A real-world data study to evaluate treatment patterns, clinical characteristics and survival outcomes for first- and second-line treatment in locally advanced and metastatic urothelial cancer patients in Germany. J. Cancer. 9, 1337\u20131348 (2018).","journal-title":"J. Cancer"},{"key":"79334_CR4","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa2312117","volume":"390","author":"T Powles","year":"2024","unstructured":"Powles, T. et al. Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer. N. Engl. J. Med. 390, 875\u2013888 (2024).","journal-title":"N. Engl. J. Med."},{"key":"79334_CR5","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1056\/NEJMoa2309863","volume":"389","author":"MS van der Heijden","year":"2023","unstructured":"van der Heijden, M. S. et al. Nivolumab plus Gemcitabine\u2013Cisplatin in Advanced Urothelial Carcinoma. N. Engl. J. Med. 389, 1778\u20131789 (2023).","journal-title":"N. Engl. J. Med."},{"key":"79334_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms22062832","volume":"22","author":"MP Scholtes","year":"2021","unstructured":"Scholtes, M. P. et al. Biomarker-oriented therapy in bladder and renal Cancer. Int. J. Mol. Sci. 22, 1\u201318 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"79334_CR7","doi-asserted-by":"publisher","DOI":"10.20517\/2394-4722.2021.171","author":"T Jun","year":"2022","unstructured":"Jun, T., Anker, J. & Galsky, M. D. Biomarkers for therapy selection in metastatic urothelial cancer. J. Cancer Metastasis Treat. vol. https:\/\/doi.org\/10.20517\/2394-4722.2021.171 (2022). 8 Preprint at.","journal-title":"J. Cancer Metastasis Treat. vol"},{"key":"79334_CR8","doi-asserted-by":"crossref","unstructured":"Eturi, A., Bhasin, A., Zarrabi, K. K. & Tester, W. J. Predictive and prognostic biomarkers and Tumor antigens for targeted therapy in Urothelial Carcinoma. Molecules 29, (2024).","DOI":"10.3390\/molecules29081896"},{"key":"79334_CR9","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1158\/1078-0432.CCR-20-4708","volume":"27","author":"H Jiang","year":"2021","unstructured":"Jiang, H. & Greenberg, R. A. Morning for irofulven, what could be fiNER? Clin. Cancer Res. 27, 1833\u20131835 (2021).","journal-title":"Clin. Cancer Res."},{"key":"79334_CR10","doi-asserted-by":"publisher","first-page":"3377","DOI":"10.1158\/1078-0432.CCR-03-0349","volume":"10","author":"J Alexandre","year":"2004","unstructured":"Alexandre, J. et al. Phase I and pharmacokinetic study of irofulven administered weekly or biweekly in advanced solid tumor patients. Clin. Cancer Res. 10, 3377\u20133385 (2004).","journal-title":"Clin. Cancer Res."},{"key":"79334_CR11","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1158\/1078-0432.CCR-20-3316","volume":"27","author":"J B\u00f6rcs\u00f6k","year":"2021","unstructured":"B\u00f6rcs\u00f6k, J. et al. Identification of a synthetic lethal relationship between nucleotide excision repair deficiency and irofulven sensitivity in urothelial cancer. Clin. Cancer Res. 27, 2011\u20132022 (2021).","journal-title":"Clin. Cancer Res."},{"key":"79334_CR12","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/S1568-7864(02)00166-0","volume":"1","author":"NGJ Jaspers","year":"2002","unstructured":"Jaspers, N. G. J. et al. Anti-tumour compounds illudin S and Irofulven induce DNA lesions ignored by global repair and exclusively processed by transcription- and replication-coupled repair pathways. DNA Repair. (Amst). 1, 1027\u20131038 (2002).","journal-title":"DNA Repair. (Amst)"},{"key":"79334_CR13","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.4161\/cbt.3.11.1306","volume":"3","author":"P Dent","year":"2004","unstructured":"Dent, P., Grant, S. & Irofulven Resurgence for alkylating therapy in cancer? Cancer Biol. Ther. 3, 1143\u20131144 (2004).","journal-title":"Cancer Biol. Ther."},{"key":"79334_CR14","doi-asserted-by":"publisher","unstructured":"Wang, X. et al. Prostaglandin Reductase 1 as a Potential Therapeutic Target for Cancer Therapy. Frontiers in Pharmacology vol. 12 Preprint at (2021). https:\/\/doi.org\/10.3389\/fphar.2021.717730","DOI":"10.3389\/fphar.2021.717730"},{"key":"79334_CR15","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1124\/jpet.112.195768","volume":"343","author":"X Yu","year":"2012","unstructured":"Yu, X. et al. Up-regulation of human prostaglandin reductase 1 improves the efficacy of hydroxymethylacylfulvene, an antitumor chemotherapeutic agent. J. Pharmacol. Exp. Ther. 343, 426\u2013433 (2012).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"79334_CR16","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-22-0818","author":"D Restifo","year":"2023","unstructured":"Restifo, D. et al. Conditional dependency of LP-184 on prostaglandin reductase 1 is synthetic lethal in pancreatic cancers with DNA damage repair deficiencies. Mol. Cancer Ther. https:\/\/doi.org\/10.1158\/1535-7163.MCT-22-0818 (2023).","journal-title":"Mol. Cancer Ther."},{"key":"79334_CR17","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.4161\/cbt.3.11.1216","volume":"3","author":"JM Woynarowski","year":"2004","unstructured":"Woynarowski, J. M. et al. Cell cycle effects and induction of premitotic apoptosis by irofulven in synchronized cancer cells. Cancer Biol. Ther. 3, 1137\u20131142 (2004).","journal-title":"Cancer Biol. Ther."},{"key":"79334_CR18","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.freeradbiomed.2016.11.027","volume":"102","author":"R S\u00e1nchez-Rodr\u00edguez","year":"2017","unstructured":"S\u00e1nchez-Rodr\u00edguez, R. et al. Ptgr1 expression is regulated by NRF2 in rat hepatocarcinogenesis and promotes cell proliferation and resistance to oxidative stress. Free Radic Biol. Med. 102, 87\u201399 (2017).","journal-title":"Free Radic Biol. Med."},{"key":"79334_CR19","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.gpb.2015.04.001","volume":"13","author":"L Tapak","year":"2015","unstructured":"Tapak, L., Saidijam, M., Sadeghifar, M., Poorolajal, J. & Mahjub, H. Competing Risks Data Analysis with High-dimensional covariates: an application in bladder Cancer. Genomics Proteom. Bioinf. 13, 169\u2013176 (2015).","journal-title":"Genomics Proteom. Bioinf."},{"key":"79334_CR20","doi-asserted-by":"crossref","unstructured":"Prosz, A. et al. Nucleotide excision repair deficiency is a targetable therapeutic vulnerability in clear cell renal cell carcinoma. Scientific Reports 2023 13:1 13, 1\u201310 (2023).","DOI":"10.1038\/s41598-023-47946-4"},{"key":"79334_CR21","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.ygyno.2005.09.036","volume":"101","author":"MV Seiden","year":"2006","unstructured":"Seiden, M. V. et al. A phase II study of irofulven in women with recurrent and heavily pretreated ovarian cancer. Gynecol. Oncol. 101, 55\u201361 (2006).","journal-title":"Gynecol. Oncol."},{"key":"79334_CR22","doi-asserted-by":"publisher","first-page":"5604","DOI":"10.1158\/1078-0432.CCR-04-0442","volume":"10","author":"F Koeppel","year":"2004","unstructured":"Koeppel, F. et al. Irofulven cytotoxicity depends on transcription-coupled nucleotide excision repair and is correlated with XPG expression in solid tumor cells. Clin. Cancer Res. 10, 5604\u20135613 (2004).","journal-title":"Clin. Cancer Res."},{"key":"79334_CR23","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1158\/1078-0432.CCR-20-3322","volume":"27","author":"S Topka","year":"2021","unstructured":"Topka, S. et al. Targeting germline- and tumor-associated nucleotide excision repair defects in cancer. Clin. Cancer Res. 27, 1997\u20132010 (2021).","journal-title":"Clin. Cancer Res."},{"key":"79334_CR24","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1158\/1078-0432.CCR-18-1001","volume":"25","author":"Q Li","year":"2019","unstructured":"Li, Q. et al. ERCC2 helicase domain mutations Confer Nucleotide Excision Repair Deficiency and Drive Cisplatin Sensitivity in muscle-invasive bladder Cancer. Clin. Cancer Res. 25, 977\u2013988 (2019).","journal-title":"Clin. Cancer Res."},{"key":"79334_CR25","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1038\/ng.3557","volume":"48","author":"J Kim","year":"2016","unstructured":"Kim, J. et al. Somatic ERCC2 mutations are associated with a distinct genomic signature in urothelial tumors. Nat. Genet. 48, 600\u2013606 (2016).","journal-title":"Nat. Genet."},{"key":"79334_CR26","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1158\/2159-8290.CD-14-0623","volume":"4","author":"EM Van Allen","year":"2014","unstructured":"Van Allen, E. M. et al. Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. Cancer Discov. 4, 1140\u20131153 (2014).","journal-title":"Cancer Discov"},{"key":"79334_CR27","doi-asserted-by":"publisher","unstructured":"Liu, D. et al. Clinical validation of chemotherapy response biomarker ERCC2 in muscle-invasive urothelial bladder carcinoma. JAMA Oncology vol. 2 1094\u20131096 Preprint at (2016). https:\/\/doi.org\/10.1001\/jamaoncol.2016.1056","DOI":"10.1001\/jamaoncol.2016.1056"},{"key":"79334_CR28","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","volume":"171","author":"AG Robertson","year":"2017","unstructured":"Robertson, A. G. et al. Comprehensive molecular characterization of muscle-invasive bladder Cancer. Cell. 171, 540\u2013556e25 (2017).","journal-title":"Cell"},{"key":"79334_CR29","doi-asserted-by":"crossref","unstructured":"Warren, S. & Simultaneous multiplexed detection of RNA and protein on the NanoString\u00ae nCounter\u00ae platform. in Methods in Molecular Biology vol. 1783 105\u2013120 (2018). (Methods Mol Biol.","DOI":"10.1007\/978-1-4939-7834-2_5"},{"key":"79334_CR30","unstructured":"NanoString Technologies Inc. MAN-C0011-04 Gene Expression Data Analysis Guidelines. (2017)."},{"key":"79334_CR31","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1214\/16-AOAS920","volume":"10","author":"B Phipson","year":"2016","unstructured":"Phipson, B., Lee, S., Majewski, I. J., Alexander, W. S. & Smyth, G. K. Robust Hyperparameter Estimation Protects Against Hypervariable Genes and Improves Power To Detect Differential Expression. Ann. Appl. Stat. 10, 946 (2016).","journal-title":"Ann. Appl. Stat."},{"key":"79334_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13059-016-0974-4","volume":"17","author":"W McLaren","year":"2016","unstructured":"McLaren, W. et al. The Ensembl variant effect predictor. Genome Biol. 17, 1\u201314 (2016).","journal-title":"Genome Biol."},{"key":"79334_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/PO.17.00011","volume":"1","author":"D Chakravarty","year":"2017","unstructured":"Chakravarty, D. et al. OncoKB: a Precision Oncology Knowledge Base. JCO Precis Oncol. 1, 1\u201316 (2017).","journal-title":"JCO Precis Oncol."},{"key":"79334_CR34","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1126\/sciadv.abj1624","volume":"8","author":"Q Li","year":"2022","unstructured":"Li, Q. et al. CancerVar: an artificial intelligence\u2013empowered platform for clinical interpretation of somatic mutations in cancer. Sci. Adv. 8, 1624 (2022).","journal-title":"Sci. Adv."},{"key":"79334_CR35","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1002\/bimj.200710415","volume":"50","author":"MD Ruopp","year":"2008","unstructured":"Ruopp, M. D., Perkins, N. J., Whitcomb, B. W. & Schisterman, E. F. Youden Index and Optimal Cut-Point estimated from observations affected by a lower limit of detection. Biom J. 50, 419 (2008).","journal-title":"Biom J."},{"key":"79334_CR36","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3","volume":"3","author":"WJ Youden","year":"1950","unstructured":"Youden, W. J. Index for rating diagnostic tests. Cancer. 3, 32\u201335 (1950).","journal-title":"Cancer"},{"key":"79334_CR37","unstructured":"R Core Team & R Core Team. (2020). Preprint at (2020). https:\/\/www.r-project.org\/"},{"key":"79334_CR38","doi-asserted-by":"crossref","unstructured":"Class, C. A., Lukan, C. J., Bristow, C. A. & Do, K. A. Easy NanoString nCounter data analysis with the NanoTube. Bioinformatics 39, (2023).","DOI":"10.1093\/bioinformatics\/btac762"},{"key":"79334_CR39","unstructured":"Hans Borchers, M. W. Title Practical Numerical Math Functions Depends R (\u2009>\u2009=\u20093.1.0). (2023)."},{"key":"79334_CR40","doi-asserted-by":"publisher","unstructured":"World Medical Association declaration of Helsinki. Ethical principles for medical research involving human subjects. JAMA vol. 310 2191\u20132194 Preprint at (2013). https:\/\/doi.org\/10.1001\/jama.2013.281053","DOI":"10.1001\/jama.2013.281053"},{"key":"79334_CR41","doi-asserted-by":"crossref","unstructured":"Prosz, A. et al. Nucleotide excision repair deficiency is a targetable therapeutic vulnerability in clear cell renal cell carcinoma. bioRxiv 11, 02.07.527498 (2023). (2023).","DOI":"10.1101\/2023.02.07.527498"},{"key":"79334_CR42","doi-asserted-by":"publisher","first-page":"461","DOI":"10.2144\/btn-2020-0095","volume":"69","author":"T MacNeil","year":"2020","unstructured":"MacNeil, T. et al. Antibody validation for protein expression on tissue slides: a protocol for immunohistochemistry. Biotechniques. 69, 461\u2013468 (2020).","journal-title":"Biotechniques"},{"key":"79334_CR43","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1093\/jnci\/dji237","volume":"97","author":"LM McShane","year":"2005","unstructured":"McShane, L. M. et al. Reporting recommendations for tumor marker prognostic studies (REMARK). J. Natl. Cancer Inst. 97, 1180\u20131184 (2005).","journal-title":"J. Natl. Cancer Inst."},{"key":"79334_CR44","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1111\/j.1365-2559.2006.02514.x","volume":"49","author":"RA Walker","year":"2006","unstructured":"Walker, R. A. Quantification of immunohistochemistry\u2013issues concerning methods, utility and semiquantitative assessment I. Histopathology. 49, 406\u2013410 (2006).","journal-title":"Histopathology"},{"key":"79334_CR45","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s007760200028","volume":"7","author":"NOB Thomsen","year":"2002","unstructured":"Thomsen, N. O. B., Olsen, L. H. & Nielsen, S. T. Kappa statistics in the assessment of observer variation: the significance of multiple observers classifying ankle fractures. J. Orthop. Sci. 7, 163\u2013166 (2002).","journal-title":"J. Orthop. Sci."},{"key":"79334_CR46","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1038\/s41588-022-01224-7","volume":"54","author":"Y Niu","year":"2022","unstructured":"Niu, Y. et al. Multiparametric and accurate functional analysis of genetic sequence variants using CRISPR-Select. Nat. Genet. 54, 1983\u20131993 (2022).","journal-title":"Nat. Genet."},{"key":"79334_CR47","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1111\/apm.13249","volume":"130","author":"T Grantzau","year":"2022","unstructured":"Grantzau, T. et al. PD-L1 expression and FGFR-mutations among Danish patients diagnosed with metastatic urothelial carcinoma: a retrospective and descriptive study. APMIS. 130, 498\u2013506 (2022).","journal-title":"APMIS"},{"key":"79334_CR48","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/s41591-021-01317-6","volume":"27","author":"T Powles","year":"2021","unstructured":"Powles, T. et al. An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer. Nat. Med. 27, 793\u2013801 (2021).","journal-title":"Nat. Med."},{"key":"79334_CR49","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1200\/JCO.22.00405","volume":"41","author":"SJ Crabb","year":"2023","unstructured":"Crabb, S. J. et al. Double-Blind, Biomarker-Selected, phase II clinical trial of maintenance poly ADP-Ribose polymerase inhibition with Rucaparib Following Chemotherapy for Metastatic Urothelial Carcinoma. J. Clin. Oncol. 41, 54\u201364 (2023). A Randomized.","journal-title":"J. Clin. Oncol."},{"key":"79334_CR50","doi-asserted-by":"crossref","unstructured":"Fulton, B. et al. ATLANTIS: a randomised multi-arm phase II biomarker-directed umbrella screening trial of maintenance targeted therapy after chemotherapy in patients with advanced or metastatic urothelial cancer. Trials 21, (2020).","DOI":"10.1186\/s13063-020-04283-5"},{"key":"79334_CR51","doi-asserted-by":"crossref","unstructured":"Sj\u00f6dahl, G. Molecular Subtype Profiling of Urothelial Carcinoma Using a subtype-specific Immunohistochemistry Panelvol. 165553\u201364 (Humana Press Inc., 2018). in Methods in Molecular Biology.","DOI":"10.1007\/978-1-4939-7234-0_5"},{"key":"79334_CR52","doi-asserted-by":"crossref","unstructured":"Ye, J. et al. Metformin escape in prostate cancer by activating the PTGR1 transcriptional program through a novel super-enhancer. Signal Transduction and Targeted Therapy 2023 8:1 8, 1\u201315 (2023).","DOI":"10.1038\/s41392-023-01516-2"},{"key":"79334_CR53","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.eururo.2019.09.006","volume":"77","author":"A Kamoun","year":"2020","unstructured":"Kamoun, A. et al. A Consensus Molecular classification of muscle-invasive bladder Cancer. Eur. Urol. 77, 420\u2013433 (2020).","journal-title":"Eur. Urol."},{"key":"79334_CR54","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.ccr.2014.01.009","volume":"25","author":"W Choi","year":"2014","unstructured":"Choi, W. et al. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell. 25, 152\u2013165 (2014).","journal-title":"Cancer Cell."},{"key":"79334_CR55","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.ebiom.2016.08.036","volume":"12","author":"V Dadhania","year":"2016","unstructured":"Dadhania, V. et al. Meta-analysis of the luminal and basal subtypes of bladder Cancer and the identification of signature immunohistochemical markers for clinical use. EBioMedicine. 12, 105\u2013117 (2016).","journal-title":"EBioMedicine"},{"key":"79334_CR56","doi-asserted-by":"crossref","unstructured":"Lavallee, E., Sfakianos, J. P. & Mulholland, D. J. Tumor heterogeneity and consequences for bladder cancer treatment. Cancers (Basel) 13, (2021).","DOI":"10.3390\/cancers13215297"},{"key":"79334_CR57","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/s41585-020-0304-1","volume":"17","author":"JJ Meeks","year":"2020","unstructured":"Meeks, J. J. et al. Genomic heterogeneity in bladder cancer: challenges and possible solutions to improve outcomes. Nat. Rev. Urol. 17, 259\u2013270 (2020).","journal-title":"Nat. Rev. Urol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-79334-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-79334-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-79334-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T13:07:01Z","timestamp":1731503221000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-79334-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,10]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["79334"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-79334-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"type":"electronic","value":"2045-2322"}],"subject":[],"published":{"date-parts":[[2024,11,10]]},"assertion":[{"value":"5 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"D.R.S. received educational and research funding from Pfizer and Merck Serono and served on advisory boards for Merck Sharp and Dome (MSD), Bristol Meyers Squibb (BMS), and Johnson and Johnson, unrelated to this study. S.L. No COI to report. B.G.T. Speaker fee from BMS unrelated to this study. L.H.D: No COI to report. L.C.M.: No COI to report. Z.S: Research funding from Lantern Pharma Inc; M.R: received personal fees from AstraZeneca and MSD and served on advisory board of MSD outside the submitted work.; H.P: Research funding from Pfizer and Merck unrelated to this study. K.W.M: Advisory\/consulting work for EMD Serono, Pfizer, UroGen, and Riva Therapeutics; has received research support from Pfizer and Novo Ventures; has equity in Riva Therapeutics; has received writing\/editor fees from UpToDate; has received speaking fees from OncLive; and is a co-inventor listed on an institutional patent application for analysis of mutational signatures of DNA repair deficiency.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"27448"}}